Umeå University Develops TriPcides That Kill MRSA and 230 Clinical Isolates Without Resistance
Updated
Updated · The Brighter Side of News · Jun 1
Umeå University Develops TriPcides That Kill MRSA and 230 Clinical Isolates Without Resistance
1 articles · Updated · The Brighter Side of News · Jun 1
Summary
Two lead TriPcides compounds killed MRSA, including drug-resistant strains and dormant persister cells, in lab tests—addressing a major cause of relapsing infections.
Across 14 serial passages, MRSA did not develop resistance to the synthetic antibiotics, and more than 230 clinical isolates remained highly sensitive, unlike earlier related compounds.
Within minutes, TriPcides disrupted bacterial membranes and respiration, drove oxidative stress, and cut persister-cell survival within 30 minutes; standard antibiotics such as ciprofloxacin and gentamicin did not match that effect.
In a mouse skin-infection model, daily SS1045B treatment shrank ulcers about 40%, while combining it with azithromycin reduced ulcer size by nearly 85%, likely by suppressing toxin-driven tissue damage.
The findings, published in Science Advances, offer an early but promising new antibiotic class as antimicrobial resistance—linked to 1.27 million direct deaths in 2019—keeps rising.